Dr. Reddy’s Laboratories (NYSE:RDY) has announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
In the study, PPC-06 met both co-primary endpoints i.e. PASI-75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks of oral treatment.
PPC-06 is an extended release formulation of a fumaric acid ester, in-licensed from Xenoport, for further development to treat moderate to severe plaque psoriasis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.